sm-346 has been researched along with Coronary-Occlusion* in 2 studies
2 other study(ies) available for sm-346 and Coronary-Occlusion
| Article | Year |
|---|---|
On the Mechanism of the Cardioprotective Action of σ
Original translational rat model of chronic heart failure provoked by experimental anterior transmural myocardium infarction was employed to examine the preventive action of anxiolytic Afobazole (15 mg/kg/day administered intraperitoneally during the first 15 days after coronary occlusion) on the development of the heart failure assessed in 3 months after infarction. Afobazole prevented the development of pathologic remodeling of the myocardium, maintained its inotropic function, and decreased the plasma level of brain natriuretic peptide known as a biochemical marker of chronic heart failure. In the myocardium, Afobazole down-regulated overexpression of the genes induced in chronic heart failure and assessed by corresponding RNA levels, which code angiotensin (AT1A-R), vasopressin (V1A-R), and glucocorticoid (GR) receptors as well as Epac2 protein. The revealed biochemical changes are consistent with the data on cardioprotective action of Afobazole. Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Outbred Strains; Anti-Anxiety Agents; Benzimidazoles; Biomarkers; Cardiotonic Agents; Coronary Occlusion; Coronary Vessels; Drug Administration Schedule; Drug Repositioning; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Heart Failure; Male; Morpholines; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Rats; Receptor, Angiotensin, Type 1; Receptors, Glucocorticoid; Receptors, Vasopressin | 2018 |
[Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation].
Influence of afobazole on cerebral blood flow in rats under conditions of global transient ischemia of brain, experimental myocardial infarction, and combined disturbances of coronary and cerebral circulation was studied in comparison to intact and sham operated animals. It is established that afobazole (5 mg/kg) enhances blood flow in parietal region of cerebral cortex of rats after global transient ischemia of brain or experimental myocardial infarction more prominently than in intact and sham operated animals. Moreover, the cerebrovascular effect of afobazole substantially increases under conditions of combined vascular pathology of brain and heart and exceeds its action observed after the cerebral ischemia or myocardial infarction. Topics: Animals; Anti-Anxiety Agents; Benzimidazoles; Cerebrovascular Circulation; Coronary Occlusion; Ischemic Attack, Transient; Male; Morpholines; Rats | 2010 |